Clinical non‐remission at post‐treatment · patients with depression
It is very uncertain whether mindfulness‐based 'third wave' cognitive and behavioural therapies changes non‐remission at post‐treatment compared with other psychological therapies (very low certainty).
1 finding from 1 review
Clinical non‐response at post‐treatment · depression
It is very uncertain whether third wave CBT changes clinical non‐response at post‐treatment compared with TAU (very low certainty).
1 finding from 1 review
Acceptability (number of participants lost to post‐treatment assessment) · depression
It is very uncertain whether third wave CBT changes treatment acceptability (dropout) at post‐treatment compared with TAU (very low certainty).
1 finding from 1 review
Clinical non‐remission at post‐treatment · depression
It is very uncertain whether third wave CBT changes clinical non‐remission at post‐treatment compared with TAU (very low certainty).
1 finding from 1 review
Anxiety · depression
1 finding from 1 review
Social adjustment levels at post‐treatment— behavioural activation vs TAU Work and Social Ajustment Scale (WSAS) · depression
1 finding from 1 review
Drop out due to inefficacy Number of participants who dropped out due to inefficacy during the trial, as a proportion of the total number of randomised participants · patients with major depression
It is very uncertain whether agomelatine changes drop out due to inefficacy Number of participants who dropped out… compared with SNRI (very low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with major depression
It is very uncertain whether agomelatine changes drop outs due to side effects Number of participants who dropped out… compared with SNRI (very low certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with major depression
It is very uncertain whether agomelatine changes total number of patients with side effects Total number of… compared with SNRI (very low certainty).
1 finding from 1 review
Total drop outs Total number of participants who dropped out during the trial as a proportion of the total number of randomised participants · patients with major depression
It is very uncertain whether agomelatine changes total drop outs Total number of participants who dropped out during… compared with SSRI (very low certainty).
1 finding from 1 review
Drop out due to inefficacy Number of participants who dropped out due to inefficacy during the trial, as a proportion of the total number of randomised participants · patients with major depression
It is very uncertain whether agomelatine changes drop out due to inefficacy Number of participants who dropped out… compared with SSRI (very low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with major depression
It is very uncertain whether agomelatine changes drop outs due to side effects Number of participants who dropped out… compared with SSRI (very low certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with major depression
It is very uncertain whether agomelatine changes total number of participants with side effects Total number of… compared with SSRI (very low certainty).
1 finding from 1 review
Total drop outs Total number of participants who dropped out during the trial as a proportion of the total number of randomised participants · patients with major depression
It is very uncertain whether agomelatine changes total drop outs Total number of participants who dropped out during… compared with SNRI (very low certainty).
1 finding from 1 review
Number relapsed‐recurred · patients with preventing relapse and recurrence of a depressive disorder in children and adolescents
Medication probably leads to lower number relapsed‐recurred compared with placebo (moderate certainty).
1 finding from 1 review
Suicide‐related behaviour · patients with preventing relapse and recurrence of a depressive disorder in children and adolescents
Medication showed no clear difference in suicide‐related behaviours compared with placebo (low certainty).
1 finding from 1 review
Total number of drop‐outs · patients with preventing relapse and recurrence of a depressive disorder in children and adolescents
Medication showed no clear difference in drop‐outs compared with placebo (moderate certainty).
1 finding from 1 review
Death due to suicide · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability of treatment Drop‐out for any reason · adults with Major Depressive Disorder
It is very uncertain whether amitriptyline changes acceptability of treatment Drop‐out for any reason compared with placebo (very low certainty).
1 finding from 1 review